Free Trial
NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

Edwards Lifesciences logo
$76.77 -0.25 (-0.32%)
Closing price 03:55 PM Eastern
Extended Trading
$76.74 -0.02 (-0.03%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Edwards Lifesciences Stock (NYSE:EW)

Key Stats

Today's Range
$76.50
$77.43
50-Day Range
$73.31
$78.34
52-Week Range
$58.93
$95.25
Volume
1.68 million shs
Average Volume
5.24 million shs
Market Capitalization
$45.03 billion
P/E Ratio
10.97
Dividend Yield
N/A
Price Target
$80.20
Consensus Rating
Hold

Company Overview

Edwards Lifesciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
87th Percentile Overall Score

EW MarketRank™: 

Edwards Lifesciences scored higher than 87% of companies evaluated by MarketBeat, and ranked 388th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Edwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 11 buy ratings, 13 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Edwards Lifesciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Edwards Lifesciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Edwards Lifesciences are expected to grow by 12.24% in the coming year, from $2.45 to $2.75 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Edwards Lifesciences is 10.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Edwards Lifesciences is 10.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 19.21.

  • Price to Earnings Growth Ratio

    Edwards Lifesciences has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Edwards Lifesciences has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Edwards Lifesciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.06% of the float of Edwards Lifesciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Edwards Lifesciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edwards Lifesciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Edwards Lifesciences does not currently pay a dividend.

  • Dividend Growth

    Edwards Lifesciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.06% of the float of Edwards Lifesciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Edwards Lifesciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edwards Lifesciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Edwards Lifesciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Edwards Lifesciences this week, compared to 25 articles on an average week.
  • Search Interest

    Only 10 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,998,866.00 in company stock.

  • Percentage Held by Insiders

    Only 1.29% of the stock of Edwards Lifesciences is held by insiders.

  • Percentage Held by Institutions

    79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Edwards Lifesciences' insider trading history.
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

EW Stock Analysis - Frequently Asked Questions

Edwards Lifesciences' stock was trading at $74.03 on January 1st, 2025. Since then, EW shares have increased by 3.7% and is now trading at $76.77.

Edwards Lifesciences Corporation (NYSE:EW) issued its earnings results on Wednesday, April, 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis.
Read the conference call transcript
.

Edwards Lifesciences's stock split on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more.

Edwards Lifesciences' top institutional shareholders include Jacobs & Co. CA (0.02%), Harbor Investment Advisory LLC, Cullen Investment Group LTD. and Neville Rodie & Shaw Inc.. Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Donald E Bobo Jr, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Daniel J Lippis, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem.
View institutional ownership trends
.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

Last Earnings
4/23/2025
Today
7/03/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:EW
Employees
15,800
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$80.20
High Stock Price Target
$95.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+4.5%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
25 Analysts

Profitability

Trailing P/E Ratio
10.97
Forward P/E Ratio
31.33
P/E Growth
3.89
Net Income
$4.17 billion
Pretax Margin
29.08%

Debt

Sales & Book Value

Annual Sales
$5.44 billion
Cash Flow
$2.72 per share
Price / Cash Flow
28.27
Book Value
$17.06 per share
Price / Book
4.50

Miscellaneous

Free Float
579,033,000
Market Cap
$45.03 billion
Optionable
Optionable
Beta
1.11

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NYSE:EW) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners